{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T22:46:10Z","timestamp":1787870770007,"version":"build-2784847793"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:00:00Z","timestamp":1760832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["NYCUKMU-112-I006"],"award-info":[{"award-number":["NYCUKMU-112-I006"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011645","name":"Kaohsiung Medical University Chung-Ho Memorial Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011645","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.diabres.2025.112947","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T23:31:23Z","timestamp":1760743883000},"page":"112947","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Urate-lowering therapy and risk of cardiorenal mortality in patients with type 2 diabetes and asymptomatic hyperuricemia"],"prefix":"10.1016","volume":"229","author":[{"given":"Chia-Fu","family":"Chuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shang-Jyh","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaw-Bin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10467","key":"10.1016\/j.diabres.2025.112947_b0005","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1016\/S0140-6736(24)02317-1","article-title":"Worldwide trends in diabetes prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants","volume":"404","author":"Zhou","year":"2024","journal-title":"Lancet"},{"issue":"Supplement_1","key":"10.1016\/j.diabres.2025.112947_b0010","first-page":"S207","article-title":"10. cardiovascular disease and risk management: standards of care in diabetes\u20142025","volume":"48","author":"Committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"10.1016\/j.diabres.2025.112947_b0015","first-page":"S1","article-title":"Introduction and methodology: standards of care in diabetes\u20142025","volume":"48","author":"Committee","year":"2024","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.diabres.2025.112947_b0020","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.amjmed.2006.06.040","article-title":"Prevalence of the metabolic syndrome in individuals with hyperuricemia","volume":"120","author":"Choi","year":"2007","journal-title":"Am J Med"},{"key":"10.1016\/j.diabres.2025.112947_b0025","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev-physiol-020911-153333","article-title":"Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney","volume":"74","author":"Vallon","year":"2012","journal-title":"Annu Rev Physiol"},{"issue":"4","key":"10.1016\/j.diabres.2025.112947_b0030","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1038\/s41584-024-01092-x","article-title":"The clinical benefits of sodium-glucose cotransporter type 2 inhibitors in people with gout","volume":"20","author":"Yokose","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"10.1016\/j.diabres.2025.112947_b0035","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2337\/dc22-1339","article-title":"Association of serum uric acid with all-cause and cardiovascular mortality in diabetes","volume":"46","author":"Li","year":"2023","journal-title":"Diabetes Care"},{"issue":"24","key":"10.1016\/j.diabres.2025.112947_b0040","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.jacc.2013.07.074","article-title":"Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy","volume":"62","author":"Szwejkowski","year":"2013","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.diabres.2025.112947_b0045","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.2169\/internalmedicine.54.4310","article-title":"The effects of allopurinol on the carotid intima-media thickness in patients with type 2 diabetes and asymptomatic hyperuricemia: a three-year randomized parallel-controlled study","volume":"54","author":"Liu","year":"2015","journal-title":"Intern Med"},{"issue":"10","key":"10.1016\/j.diabres.2025.112947_b0050","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1007\/s00125-005-1896-y","article-title":"The epidemiology of left ventricular hypertrophy in type 2 diabetes mellitus","volume":"48","author":"Dawson","year":"2005","journal-title":"Diabetologia"},{"issue":"6","key":"10.1016\/j.diabres.2025.112947_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2024.103043","article-title":"Association between urate-lowering therapy initiation and all-cause mortality in patients with type 2 diabetes and asymptomatic hyperuricemia","volume":"18","author":"Chen","year":"2024","journal-title":"Diabetes Metab Syndr"},{"issue":"6","key":"10.1016\/j.diabres.2025.112947_b0060","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American college of rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.diabres.2025.112947_b0065","article-title":"Japanese society of gout and uric & nucleic acids 2019 guidelines for management of hyperuricemia and gout 3rd edition","volume":"44","author":"Hisatome","year":"2020","journal-title":"Gout Uric Nucleic Acids"},{"issue":"4","key":"10.1016\/j.diabres.2025.112947_b0070","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/1756-185X.13266","article-title":"Management of gout and hyperuricemia: multidisciplinary consensus in Taiwan","volume":"21","author":"Yu","year":"2018","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.diabres.2025.112947_b0075","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1136\/bmj.b5087","article-title":"Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes","volume":"340","author":"L\u00e9vesque","year":"2010","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.diabres.2025.112947_b0080","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/aje\/kwi307","article-title":"Survival bias associated with time-to-treatment initiation in drug effectiveness evaluation: a comparison of methods","volume":"162","author":"Zhou","year":"2005","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10.1016\/j.diabres.2025.112947_b0085","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/j.jdiacomp.2017.02.018","article-title":"Diabetes complications severity index (DCSI)-Update and ICD-10 translation","volume":"31","author":"Glasheen","year":"2017","journal-title":"J Diabetes Complications"},{"issue":"2","key":"10.1016\/j.diabres.2025.112947_b0090","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2022-003262","article-title":"Adapted diabetes complications severity index and Charlson comorbidity index in predicting all-cause and cause-specific mortality among patients with type 2 diabetes","volume":"11","author":"Hu","year":"2023","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"19","key":"10.1016\/j.diabres.2025.112947_b0095","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.diabres.2025.112947_b0100","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1002\/pst.433","article-title":"Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies","volume":"10","author":"Austin","year":"2011","journal-title":"Pharm Stat"},{"issue":"6","key":"10.1016\/j.diabres.2025.112947_b0105","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1080\/03610910902859574","article-title":"Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research","volume":"38","author":"Austin","year":"2009","journal-title":"Commun Stat-Simulat Comput"},{"issue":"25","key":"10.1016\/j.diabres.2025.112947_b0110","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med"},{"issue":"4","key":"10.1016\/j.diabres.2025.112947_b0115","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.diabres.2025.112947_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jss.2020.11.023","article-title":"Clinical stage of cancer affects perioperative mortality for gastrointestinal cancer surgeries","volume":"260","author":"Bliton","year":"2021","journal-title":"J Surg Res"},{"issue":"446","key":"10.1016\/j.diabres.2025.112947_b0125","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"issue":"1","key":"10.1016\/j.diabres.2025.112947_b0130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/EDE.0000000000000565","article-title":"Bias due to confounders for the exposure-competing risk relationship","volume":"28","author":"Lesko","year":"2017","journal-title":"Epidemiology"},{"key":"10.1016\/j.diabres.2025.112947_b0135","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jclinepi.2020.03.004","article-title":"Ignoring competing events in the analysis of survival data may lead to biased results: a nonmathematical illustration of competing risk analysis","volume":"122","author":"Schuster","year":"2020","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.diabres.2025.112947_b0140","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001944","article-title":"Increased risk of cardiovascular events and death in the initial phase after discontinuation of febuxostat or allopurinol: another story of the CARES trial","volume":"8","author":"Ghang","year":"2022","journal-title":"RMD Open"},{"issue":"11","key":"10.1016\/j.diabres.2025.112947_b0145","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.1007\/s10067-023-06710-9","article-title":"Association between urate-lowering therapy and cardiovascular events in patients with asymptomatic hyperuricemia","volume":"42","author":"Hashimoto","year":"2023","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.diabres.2025.112947_b0150","article-title":"Effect of urate-lowering therapy on the progression of kidney function in patients with asymptomatic hyperuricemia: a systematic review and meta-analysis","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"9","key":"10.1016\/j.diabres.2025.112947_b0155","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1097\/HJH.0000000000003484","article-title":"Urate-lowering drugs for chronic kidney disease with asymptomatic hyperuricemia and hypertension: a randomized trial","volume":"41","author":"Kohagura","year":"2023","journal-title":"J Hypertens"},{"issue":"26","key":"10.1016\/j.diabres.2025.112947_b0160","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1056\/NEJMoa1915833","article-title":"Effects of allopurinol on the progression of chronic kidney disease","volume":"382","author":"Badve","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.diabres.2025.112947_b0165","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","article-title":"Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial","volume":"72","author":"Kimura","year":"2018","journal-title":"Am J Kidney Dis"},{"issue":"22","key":"10.1016\/j.diabres.2025.112947_b0170","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/eurheartj\/ehz119","article-title":"Febuxostat for cerebral and cardiorenovascular events prevention study","volume":"40","author":"Kojima","year":"2019","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.diabres.2025.112947_b0175","doi-asserted-by":"crossref","first-page":"e400","DOI":"10.1007\/s11926-013-0400-9","article-title":"The crystallization of monosodium urate","volume":"16","author":"Martillo","year":"2014","journal-title":"Curr Rheumatol Rep"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725009611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822725009611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T03:53:53Z","timestamp":1773201233000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822725009611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":35,"alternative-id":["S0168822725009611"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112947","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Urate-lowering therapy and risk of cardiorenal mortality in patients with type 2 diabetes and asymptomatic hyperuricemia","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2025.112947","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112947"}}